Orlucent, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.orlucent.com
Clinical Trials
7
Active:0
Completed:5
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
INTER-PATHOLOGIST READER STUDY
- Conditions
- Nevi, Dysplastic
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Orlucent, Inc
- Target Recruit Count
- 500
- Registration Number
- NCT06246903
- Locations
- 🇺🇸
University of Utah Hospital, Pathology, Salt Lake City, Utah, United States
Skin Fluorescent Imaging (SFI) System in Patients With Nevi
- Conditions
- NevusDysplasia; Epithelial
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Orlucent, Inc
- Target Recruit Count
- 300
- Registration Number
- NCT04368247
- Locations
- 🇺🇸
Center for Dermatology Clinical Research, Inc, Fremont, California, United States
🇺🇸Quest Dermatology Research, Northridge, California, United States
🇺🇸Solano Dermatology Associates, Vallejo, California, United States
Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)
Completed
- Conditions
- MoleSkin LesionMelanoma (Skin)
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Orlucent, Inc
- Target Recruit Count
- 186
- Registration Number
- NCT03535077
- Locations
- 🇺🇸
Center for Dermatology Clinical Research, Inc, Fremont, California, United States
🇺🇸UCI Center for Clinical Research, Irvine, California, United States
🇺🇸Divya Railan, Md, Faad, Menlo Park, California, United States
Investigating the Clinical Utility of the MDS
Completed
- Conditions
- MolesSkin LesionMelanoma
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Orlucent, Inc
- Target Recruit Count
- 250
- Registration Number
- NCT03109327
- Locations
- 🇬🇧
NHS Lanarkshire, Monklands Hospital, Airdrie, United Kingdom
Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging
Completed
- Conditions
- Skin Lesion
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- Orlucent, Inc
- Target Recruit Count
- 50
- Registration Number
- NCT02193581
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
- Prev
- 1
- 2
- Next
News
No news found